Prinomastat

N/A

Report date: 2022/10/08 20:01:01
NME

Base Information

Drug NamePrinomastat
Drug Alias NamePrinomastatum普啉司他普马司他CytaqAG 3362 (maleate) +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMatrix metalloproteinase inhibitors
TargetsMatrix metalloproteinase
Therapy Area/IndicationsCNS Embryonal TumorProstatic NeoplasmsLung Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesChengdu Zenitar Biomedical Technology Co Ltd
Inactive CompaniesPfizer Inc
Active IndicationsLymphoma, Large B-Cell, Diffuse
Inactive IndicationsCNS Embryonal TumorProstatic NeoplasmsLung Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG